From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?

Swetha Byravan,Harini Samarasinghe,Jack Shi Jie Yuan,Syed Haider Tahir,Arumugam Moorthy,Hasan Tahir
DOI: https://doi.org/10.1080/13543784.2024.2351505
2024-05-10
Expert Opinion on Investigational Drugs
Abstract:Introduction IL-17 has been described as a pro-inflammatory cytokine that is relevant in the seronegative spondylarthritides with IL-17 targeted therapies being licensed for their treatment. There is evidence to demonstrate that IL-17 is found in RA joints and contributes to the pro-inflammatory cascade. This results in synovial hyperplasia and osteoclastogenesis thus causing joint destruction and bony erosions.
pharmacology & pharmacy
What problem does this paper attempt to address?